Effect of GPIIb/IIIa + vβ3, GPIb, and GPIa/IIa Blockade on Thrombin Generation in PRP in the Presence and Absence of Fibrin Clots
| Conditions . | Fibrin Clots . | No. . | ETP % . | PeakThrombin % . | PDMP % . | PMPA % . | Residual Factor II % . |
|---|---|---|---|---|---|---|---|
| Control | − | 16 | 100 | 100 | 100 | 100 | 12 ± 2 |
| + | 16 | 142 ± 4 | 164 ± 11 | 144 ± 7 | 178 ± 12 | 6 ± 1 | |
| Anti-GPIIb/IIIa + αvβ3 | − | 10 | 42 ± 4 | 41 ± 4 | 44 ± 6 | 42 ± 3 | 32 ± 1 |
| (7E3) | + | 10 | 92 ± 6 | 89 ± 9 | 91 ± 6 | 72 ± 10 | 20 ± 2 |
| d-RGDW (60 μmol/L) | − | 4 | 60 | 49 | 56 | 74 | 25 |
| + | 4 | 98 | 83 | 72 | 90 | 11 | |
| Anti-GPIb | |||||||
| 6D1 | − | 6 | 98 ± 7 | 95 ± 8 | 99 ± 11 | 97 ± 11 | 14 ± 2 |
| + | 6 | 85 ± 9 | 96 ± 14 | 92 ± 14 | 95 ± 15 | 12 ± 3 | |
| AP-1 | − | 3 | 101 | 94 | 100 | 104 | 13 |
| + | 3 | 97 | 97 | 95 | 98 | 14 | |
| CD42b | − | 3 | 103 | 98 | 98 | 95 | 12 |
| + | 3 | 93 | 95 | 104 | 87 | 14 | |
| Anti-GPIIb/IIIa + GPIb | − | 3 | 46 | 59 | 49 | 37 | 32 |
| (7E3 and 6D1) | + | 3 | 51 | 57 | 55 | 40 | 30 |
| Anti-GPIa/IIa | − | 4 | 105 | 100 | 98 | 104 | 11 |
| (6F1) | + | 4 | 135 | 171 | 148 | 150 | 7 |
| Anti-GPIIb/IIIa + Ia/IIa | − | 3 | 58 | 55 | 49 | 47 | 26 |
| (7E3 & 6F1) | + | 3 | 90 | 89 | 101 | 73 | 19 |
| Ionomycin (10 μmol/L) | − | 14 | 139 ± 4 | 145 ± 9 | 154 ± 14 | 147 ± 9 | 6 ± 1 |
| (see legend) | + | 14 | 136 ± 4 | 140 ± 10 | 144 ± 16 | 152 ± 9 | 6 ± 1 |
| Conditions . | Fibrin Clots . | No. . | ETP % . | PeakThrombin % . | PDMP % . | PMPA % . | Residual Factor II % . |
|---|---|---|---|---|---|---|---|
| Control | − | 16 | 100 | 100 | 100 | 100 | 12 ± 2 |
| + | 16 | 142 ± 4 | 164 ± 11 | 144 ± 7 | 178 ± 12 | 6 ± 1 | |
| Anti-GPIIb/IIIa + αvβ3 | − | 10 | 42 ± 4 | 41 ± 4 | 44 ± 6 | 42 ± 3 | 32 ± 1 |
| (7E3) | + | 10 | 92 ± 6 | 89 ± 9 | 91 ± 6 | 72 ± 10 | 20 ± 2 |
| d-RGDW (60 μmol/L) | − | 4 | 60 | 49 | 56 | 74 | 25 |
| + | 4 | 98 | 83 | 72 | 90 | 11 | |
| Anti-GPIb | |||||||
| 6D1 | − | 6 | 98 ± 7 | 95 ± 8 | 99 ± 11 | 97 ± 11 | 14 ± 2 |
| + | 6 | 85 ± 9 | 96 ± 14 | 92 ± 14 | 95 ± 15 | 12 ± 3 | |
| AP-1 | − | 3 | 101 | 94 | 100 | 104 | 13 |
| + | 3 | 97 | 97 | 95 | 98 | 14 | |
| CD42b | − | 3 | 103 | 98 | 98 | 95 | 12 |
| + | 3 | 93 | 95 | 104 | 87 | 14 | |
| Anti-GPIIb/IIIa + GPIb | − | 3 | 46 | 59 | 49 | 37 | 32 |
| (7E3 and 6D1) | + | 3 | 51 | 57 | 55 | 40 | 30 |
| Anti-GPIa/IIa | − | 4 | 105 | 100 | 98 | 104 | 11 |
| (6F1) | + | 4 | 135 | 171 | 148 | 150 | 7 |
| Anti-GPIIb/IIIa + Ia/IIa | − | 3 | 58 | 55 | 49 | 47 | 26 |
| (7E3 & 6F1) | + | 3 | 90 | 89 | 101 | 73 | 19 |
| Ionomycin (10 μmol/L) | − | 14 | 139 ± 4 | 145 ± 9 | 154 ± 14 | 147 ± 9 | 6 ± 1 |
| (see legend) | + | 14 | 136 ± 4 | 140 ± 10 | 144 ± 16 | 152 ± 9 | 6 ± 1 |
The final concentration of each MoAb used was 20 μg/mL. d-RGDW was used at 60 μmol/L, ionomycin at 10 μmol/L. None of the antibodies had a measurable effect on thrombin generation in the presence of ionomycin, so all values were pooled in this case. Values are expressed as mean ± SEM and as a percentage of a normal control assayed concomitantly, except for the residual prothrombin content in the serum (last column), which is expressed as % of the original prothrombin content of the plasma. No SEM is given if n < 5; individual values were within 15% of the mean.
Abbreviations: ETP, endogenous thrombin potential; peak thrombin, highest thrombin concentration observed; PDMP, platelet derived, annexin V-positive microparticles; PMPA, platelet membrane-derived procoagulant phospholipid activity.